2bind offers tailor-made analytical services for Drug Discovery and Antibody Research.
2bind has a track record of over 600 completed projects. We have worked with 6 of the top 10 global pharma companies, as well as with more than 60 SMEs and with over 25 universities (e.g. MIT, Stanford) on more than 300 targets.
2bind is the first service provider certified by NanoTemper Technologies for nanoDSF and MicroScale Thermophoresis.
Services for early drug discovery:
Services for Antibody Research:
2bind offers milestone-based projects to solve scientific questions using biophysical approaches, enabling our customers to have full control of the project, of the budget and of the timelines.
Services for Drug Discovery and Development:
Based on our core technologies MicroScale Thermophoresis and nanoDSF (2bind was the first service provider certified for MST and nanoDSF by NanoTemper Technologies) we do offer HTS approaches and frragment screenings (with access to 150 K compound library and fragment library).
In addition, 2bind offers hit validation and characterisation using MST, nanoDSF, BLI and ITC.
Services for Antibody discovery and development:
We offer assays to identify, validate and characterize AB hits. Furthermore, we do offer assays to optimize chemical, conformational and colloidal stability of ABs
Our FDA plate (TM) is a buffer library containing 96 buffer systems of FDA / EMA approved ABs and offers an educated way of pre-formulation. These buffers have already shown their beneficial influence on ABs.